Curio Biotech : a 3RCC grant and two Novel Serum-Free Viral Transport Media

Curio Biotech SA from BioArk Visp is participating as a co-applicant in a new research project funded by the Swiss 3R Competence Centre (3RCC). Since the outbreak of the pandemic, the start-up has developed two novel serum-free media for viral sample collection and transport for Covid-19 diagnostic testing.

Founded in January 2017 and established at BioArk Visp, Curio Biotech SA is a CRO providing research services to clients in the pharma, diagnostic and cosmetic sectors. For all services related to primary human cells and new 3D reconstructed models, the start-up uses human cell culture media formulations developed in-house. Curio Biotech SA is supported by The Ark’ Incubator.

An alternative to animal experimentation
Curio Biotech SA from BioArk Visp is proud to be participating as a co-applicant in a new research project funded by the Swiss 3R Competence Centre (3RCC). This grant was approved after a competitive selection process to develop a novel model for studying toxicity and transfer of drugs or foreign substances to the growing embryo. This model aims to reduce the need for animal experimentation.  

Two Validated Serum-Free Viral Transport Media
Two novel serum-free media for patient viral samples collection and transport have been developed for Covid-19 diagnostic testing. Both media has been validated externally (spike tests and RT-PCR). The serum-free and totally defined media formulation has a high potential for vaccine production use. Viral Transport Media will be made available to public hospitals and institutions in Switzerland without profit by Curio Biotech SA.

Source : Curio Biotech